The Selective Use of Radiation Therapy in Rectal Cancer Patients
- 90 Downloads
Purpose of Review
Colorectal cancer has a high global incidence, and standard treatment employs a multimodality approach. In addition to cure, minimizing treatment-related toxicity and improving the therapeutic ratio is a common goal. The following article addresses the potential of omitting radiotherapy in select rectal cancer patients.
Omission of radiotherapy in rectal cancer is analyzed in the context of historical findings, as well as more recent data describing risk stratification of stage II–III disease, surgical optimization, imaging limitations, improvement in systemic chemotherapeutic agents, and contemporary studies evaluating selective omission of radiotherapy.
A subset of rectal cancer patients exists that may be considered low to intermediate risk for locoregional recurrence. With appropriate staging, surgical technique, and possibly improved systemic therapy, it may be feasible to selectively omit radiotherapy in these patients. Current imaging limitations as well as evidence of increased locoregional recurrence following radiotherapy omission lend us to continue supporting the standard treatment of approach of neoadjuvant chemoradiation therapy followed by surgical resection until additional improvements and prospective evidence can support otherwise.
KeywordsRadiotherapy omission Rectal cancer Risk stratification rectal cancer Imaging rectal cancer Minimizing toxicity Prognostic factors rectal cancer
Compliance with Ethical Standards
Conflict of Interest
Andrew Martella declares that he has no conflict of interest.
Christopher Willett declares that he has no conflict of interest.
Manisha Palta has received research support from Merck and honoraria from Oakstone CME and UpToDate.
Brian Czito declares that he has no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 5.Wolmark N, Wieand HS, Hyams DM, Colangelo L, Dimitrov NV, Romond EH, et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst. 2000;92(5):388–96.CrossRefPubMedGoogle Scholar
- 10.Gerard A, Buyse M, Nordlinger B, Loygue J, Pene F, Kempf P, et al. Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC). Ann Surg. 1988;208(5):606–14.CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Minsky BD, Conti JA, Huang Y, Knopf K. Relationship of acute gastrointestinal toxicity and the volume of irradiated small bowel in patients receiving combined modality therapy for rectal cancer. J Clin Oncol. 1995;13(6):1409–16. https://doi.org/10.1200/JCO.19184.108.40.2069.CrossRefPubMedGoogle Scholar
- 25.Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009;373(9666):811–20. https://doi.org/10.1016/S0140-6736(09)60484-0.CrossRefPubMedPubMedCentralGoogle Scholar
- 26.• Harris DA, Thorne K, Hutchings H, Islam S, Holland G, Hatcher O, et al. Protocol for a multicentre randomised feasibility trial evaluating early surgery alone in LOw rectal cancer (SAILOR). BMJ Open. 2016;6(11):e012496. https://doi.org/10.1136/bmjopen-2016-012496. This is a feasibility study that will help guide future trials evaluating surgery alone in the treatment of rectal cancer. CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926–33. https://doi.org/10.1200/JCO.2011.40.1836.CrossRefPubMedGoogle Scholar
- 29.• Schrag D, Weiser MR, Goodman KA, Gonen M, Hollywood E, Cercek A, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol. 2014;32(6):513–8. https://doi.org/10.1200/JCO.2013.51.7904. Contemporary pilot trial providing feasibility evidence for the use of chemotherapy without radiotherapy to support necessary larger randomized trials. CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Ishii Y, Hasegawa H, Endo T, Okabayashi K, Ochiai H, Moritani K, et al. Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer. Eur J Surg Oncol. 2010;36(11):1061–5. https://doi.org/10.1016/j.ejso.2010.05.017.CrossRefPubMedGoogle Scholar
- 32.•• Fernandez-Martos C, Brown G, Estevan R, Salud A, Montagut C, Maurel J, et al. Preoperative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by high-resolution magnetic resonance imaging: the GEMCAD 0801 phase II multicenter trial. Oncologist. 2014;19(10):1042–3. https://doi.org/10.1634/theoncologist.2014-0233. Highlights the need for imaging to keep pace with changing treatment approaches, and allows us to make more personalized decisions regarding treatment. CrossRefPubMedPubMedCentralGoogle Scholar
- 33.•• Deng Y, Chi P, Lan P, Wang L, Chen W, Cui L, et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial. J Clin Oncol. 2016;34(27):3300–7. https://doi.org/10.1200/JCO.2016.66.6198. Provides evidence of efficacy and feasibility of using modified chemotherapeutic regimens that can obtain similar downstaging but inferior pathological response rates to a radiation-based approach. Highlights the importance that these new regimens must maintain appropriate degree of efficacy without additional toxicity. CrossRefPubMedGoogle Scholar